Process chemistry

Annovis Bio Announces First Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, May 11, 2023
Teva Pharmaceuticals, Patent, Metal, Human, Gian Maria Annovi, PD, Alzheimer's disease, Environmental Toxicology and Pharmacology, United States Patent and Trademark Office, Clinical trial, Toxicology, ATM, Down syndrome, International Conference on Afghanistan, London (2006), Patient, Procházka, Process chemistry, Mouse, Research, AD, FDA, News, NYSE, Conference, Chemical process, Pharmaceutical industry, EU, Pharmacology

BERWYN, Pa., May 11, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company addressing neurodegenerative diseases, announced first quarter financial results for the period ended March 31, 2023, and reviewed recent accomplishments.

Key Points: 
  • BERWYN, Pa., May 11, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company addressing neurodegenerative diseases, announced first quarter financial results for the period ended March 31, 2023, and reviewed recent accomplishments.
  • At a recent R&D webcast on April 20, 2023, the Company:
    Reviewed its ongoing clinical programs in AD and PD.
  • Explained the results from the pre-planned blinded interim analysis of the ongoing Phase 3 study for early PD, announced on March 31, 2023.
  • Financial Results (for the quarter ending March 31, 2023)
    Cash and cash equivalents were $16.8 million.

Sai Life Sciences opens SSRL, a dedicated research facility for Schrödinger, at its Hyderabad R&D Campus

Retrieved on: 
Thursday, April 20, 2023
Medicinal chemistry, Analytical chemistry, Therapy, SSRL, Full-time equivalent, Development, Contract research organization, Commerce, Drug discovery, Process chemistry, Biology, ADME, Sai, Fine chemical, Pharmaceutical industry

HYDERABAD, India, April 20, 2023 /PRNewswire/ -- Sai Life Sciences, one of India's fastest growing global Contract Research, Development & Manufacturing Organisations (CRO-CDMO), today announced the opening of Sai Schrödinger Research Laboratories (SSRL) at its R&D campus in Hyderabad, India. The facility was inaugurated by Dr. Karen Akinsanya, President of R&D, Therapeutics at Schrödinger Inc., in the presence of members of the leadership team of Schrödinger and Sai Life Sciences.

Key Points: 
  • HYDERABAD, India, April 20, 2023 /PRNewswire/ -- Sai Life Sciences, one of India's fastest growing global Contract Research, Development & Manufacturing Organisations (CRO-CDMO) , today announced the opening of Sai Schrödinger Research Laboratories (SSRL) at its R&D campus in Hyderabad, India.
  • The facility was inaugurated by Dr. Karen Akinsanya, President of R&D, Therapeutics at Schrödinger Inc., in the presence of members of the leadership team of Schrödinger and Sai Life Sciences.
  • Speaking at the occasion, Krishna Kanumuri, CEO & Managing Director, Sai Life Sciences, said, "Our collaboration with Schrödinger marks an exciting new start for us at Sai Life Sciences, with a dedicated facility to support multiple discovery programs.
  • Set up inside Sai Life Sciences' R&D campus in Genome Valley, SSRL is a dedicated facility for integrated discovery work streams including medicinal & synthetic chemistry , in vitro biology , and process chemistry .

Sai Life Sciences opens SSRL, a dedicated research facility for Schrödinger, at its Hyderabad R&D Campus

Retrieved on: 
Thursday, April 20, 2023
Medicinal chemistry, Analytical chemistry, Therapy, SSRL, Full-time equivalent, Development, Contract research organization, Commerce, Drug discovery, Process chemistry, Biology, ADME, Sai, Fine chemical, Pharmaceutical industry

HYDERABAD, India, April 20, 2023 /PRNewswire/ -- Sai Life Sciences, one of India's fastest growing global Contract Research, Development & Manufacturing Organisations (CRO-CDMO), today announced the opening of Sai Schrödinger Research Laboratories (SSRL) at its R&D campus in Hyderabad, India. The facility was inaugurated by Dr. Karen Akinsanya, President of R&D, Therapeutics at Schrödinger Inc., in the presence of members of the leadership team of Schrödinger and Sai Life Sciences.

Key Points: 
  • HYDERABAD, India, April 20, 2023 /PRNewswire/ -- Sai Life Sciences, one of India's fastest growing global Contract Research, Development & Manufacturing Organisations (CRO-CDMO) , today announced the opening of Sai Schrödinger Research Laboratories (SSRL) at its R&D campus in Hyderabad, India.
  • The facility was inaugurated by Dr. Karen Akinsanya, President of R&D, Therapeutics at Schrödinger Inc., in the presence of members of the leadership team of Schrödinger and Sai Life Sciences.
  • Speaking at the occasion, Krishna Kanumuri, CEO & Managing Director, Sai Life Sciences, said, "Our collaboration with Schrödinger marks an exciting new start for us at Sai Life Sciences, with a dedicated facility to support multiple discovery programs.
  • Set up inside Sai Life Sciences' R&D campus in Genome Valley, SSRL is a dedicated facility for integrated discovery work streams including medicinal & synthetic chemistry , in vitro biology , and process chemistry .

Sai Life Sciences sets up GMP Kilo Lab in Alderley Park, Manchester, UK

Retrieved on: 
Wednesday, March 15, 2023
CGMP, Drug discovery, Contract research organization, GMP, Investment, COE, Center of excellence, Filtration, Development, Process chemistry, NCE, Fine chemical

MANCHESTER, England and HYDERABAD, India, March 15, 2023 /PRNewswire/ -- Sai Life Sciences, a leading global Contract Research, Development & Manufacturing Organization (CRO-CDMO) , today announced the setting up of a GMP Kilo Lab at its facility in Alderley Park, Manchester, UK.

Key Points: 
  • MANCHESTER, England and HYDERABAD, India, March 15, 2023 /PRNewswire/ -- Sai Life Sciences, a leading global Contract Research, Development & Manufacturing Organization (CRO-CDMO) , today announced the setting up of a GMP Kilo Lab at its facility in Alderley Park, Manchester, UK.
  • The new GMP Kilo Lab will enable Sai Life Sciences to offer drug substance and intermediates supplies ranging from gram to kilogram quantities to meet customer clinical requirements at an accelerated pace.
  • Making the announcement, Sauri Gudlavalleti, COO of Sai Life Sciences, said, "The new lab, located closer to our customers, has been set up with comprehensive cGMP controls and world-class infrastructure.
  • The lab also offers analytical method validation and analytical services to support batch release, in additional to stability studies to enable rapid regulatory filing.

Sai Life Sciences sets up GMP Kilo Lab in Alderley Park, Manchester, UK

Retrieved on: 
Wednesday, March 15, 2023
CGMP, Drug discovery, Contract research organization, GMP, Investment, COE, Center of excellence, Filtration, Development, Process chemistry, NCE, Fine chemical

MANCHESTER, England and HYDERABAD, India, March 15, 2023 /PRNewswire/ -- Sai Life Sciences, a leading global Contract Research, Development & Manufacturing Organization (CRO-CDMO) , today announced the setting up of a GMP Kilo Lab at its facility in Alderley Park, Manchester, UK.

Key Points: 
  • MANCHESTER, England and HYDERABAD, India, March 15, 2023 /PRNewswire/ -- Sai Life Sciences, a leading global Contract Research, Development & Manufacturing Organization (CRO-CDMO) , today announced the setting up of a GMP Kilo Lab at its facility in Alderley Park, Manchester, UK.
  • The new GMP Kilo Lab will enable Sai Life Sciences to offer drug substance and intermediates supplies ranging from gram to kilogram quantities to meet customer clinical requirements at an accelerated pace.
  • Making the announcement, Sauri Gudlavalleti, COO of Sai Life Sciences, said, "The new lab, located closer to our customers, has been set up with comprehensive cGMP controls and world-class infrastructure.
  • The lab also offers analytical method validation and analytical services to support batch release, in additional to stability studies to enable rapid regulatory filing.

Sai Life Sciences inks strategic agreement to set up Schrödinger's first dedicated offshore Research Laboratories in India

Retrieved on: 
Tuesday, January 10, 2023
Process chemistry, Drug discovery, Contract research organization, Research, Laboratory, ADME, Growth, Biology, Development, Discovery, Sai, Investment, Therapy, Medicinal chemistry, Analytical chemistry, Chemistry, FTE, SSRL, Fine chemical

HYDERABAD, India, Jan. 10, 2023 /PRNewswire/ -- Sai Life Sciences, one of India's fastest growing global Contract Research, Development & Manufacturing Organisations (CRO-CDMO), today announced that it has entered a 5-year strategic agreement with Schrödinger, whose physics-based computational platform is transforming the way therapeutics and materials are discovered, to set up the Sai Schrödinger Research Laboratories (SSRL) in Hyderabad, India.

Key Points: 
  • HYDERABAD, India, Jan. 10, 2023 /PRNewswire/ -- Sai Life Sciences, one of India's fastest growing global Contract Research, Development & Manufacturing Organisations (CRO-CDMO), today announced that it has entered a 5-year strategic agreement with Schrödinger, whose physics-based computational platform is transforming the way therapeutics and materials are discovered, to set up the Sai Schrödinger Research Laboratories (SSRL) in Hyderabad, India.
  • Being built inside Sai Life Sciences' R&D campus in genome valley, Hyderabad, SSRL will be a dedicated facility for integrated discovery work streams including medicinal & synthetic chemistry , in vitro biology , and process chemistry .
  • It will access other Sai capabilities such as in vitro ADME and in vivo PK as needed.
  • Making the announcement, Krishna Kanumuri, CEO & Managing Director, Sai Life Sciences, said, "We're truly delighted that Schrödinger has decided to partner with Sai Life Sciences to set-up their first offshore research laboratories.

Sai Life Sciences inks strategic agreement to set up Schrödinger's first dedicated offshore Research Laboratories in India

Retrieved on: 
Tuesday, January 10, 2023
Process chemistry, Drug discovery, Contract research organization, Research, Laboratory, ADME, Growth, Biology, Development, Discovery, Sai, Investment, Therapy, Medicinal chemistry, Analytical chemistry, Chemistry, FTE, SSRL, Fine chemical

HYDERABAD, India, Jan. 10, 2023 /PRNewswire/ -- Sai Life Sciences, one of India's fastest growing global Contract Research, Development & Manufacturing Organisations (CRO-CDMO), today announced that it has entered a 5-year strategic agreement with Schrödinger, whose physics-based computational platform is transforming the way therapeutics and materials are discovered, to set up the Sai Schrödinger Research Laboratories (SSRL) in Hyderabad, India.

Key Points: 
  • HYDERABAD, India, Jan. 10, 2023 /PRNewswire/ -- Sai Life Sciences, one of India's fastest growing global Contract Research, Development & Manufacturing Organisations (CRO-CDMO), today announced that it has entered a 5-year strategic agreement with Schrödinger, whose physics-based computational platform is transforming the way therapeutics and materials are discovered, to set up the Sai Schrödinger Research Laboratories (SSRL) in Hyderabad, India.
  • Being built inside Sai Life Sciences' R&D campus in genome valley, Hyderabad, SSRL will be a dedicated facility for integrated discovery work streams including medicinal & synthetic chemistry , in vitro biology , and process chemistry .
  • It will access other Sai capabilities such as in vitro ADME and in vivo PK as needed.
  • Making the announcement, Krishna Kanumuri, CEO & Managing Director, Sai Life Sciences, said, "We're truly delighted that Schrödinger has decided to partner with Sai Life Sciences to set-up their first offshore research laboratories.

FMC Corporation announces planned retirement of executive vice president and CTO Dr. Kathleen Shelton, Dr. Seva Rostovtsev appointed vice president and CTO

Retrieved on: 
Wednesday, December 14, 2022
Chemical industry, Innovation, Retirement, Food, Crop protection, R, Environment, FMC Corporation, Trustee, Risk, Research, Science, FMC, Inclusion, NYSE, Regulatory affairs, Emerging technologies, Seva, Health, Click chemistry, DuPont, Nobel Prize in Chemistry, National Operating Committee on Standards for Athletic Equipment, Rostovtsev, Nobel Prize, Multimedia, DuPont Central Research, Equity, Scripps Research, Farmer, Process chemistry, University Foundation, Student, United Way, Diversity, Management, Fine chemical, Chemistry, Engineering

FMC Corporation (NYSE: FMC) has announced the planned retirement of Dr. Kathleen Shelton, executive vice president and chief technology officer (CTO), following a 33-year career in the chemical industry.

Key Points: 
  • FMC Corporation (NYSE: FMC) has announced the planned retirement of Dr. Kathleen Shelton, executive vice president and chief technology officer (CTO), following a 33-year career in the chemical industry.
  • Dr. Seva Rostovtsev, director of Discovery Chemistry, has been elected vice president and CTO by the board of directors.
  • Shelton and Rostovtsev will transition responsibilities as part of the succession plan during the next several months until her retirement on March 31, 2023.
  • On behalf of all of us at FMC, I thank her for her leadership and lasting contributions at our company.

Pharmaron Appoints Dr. Antony Davies as Senior Vice President, UK CMC

Retrieved on: 
Monday, January 17, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, MSD, Doctor of Philosophy, Research, East Anglia, CMC, D, Cass Business School, MBA, Chemistry, CEO, Process, Solution, GMP, CGT, Industry, CGMP, Control, Process chemistry, API, Drug discovery, Senior, University of East Anglia, Management, Fine chemical, Hoddesdon

Pharmaron Beijing Co., Limited (Stock Code: 300759.SZ/3759.HK) (Pharmaron) today announced the appointment of Dr. Antony (Tony) Davies as Senior Vice President, UK CMC, effective January 10, 2022.

Key Points: 
  • Pharmaron Beijing Co., Limited (Stock Code: 300759.SZ/3759.HK) (Pharmaron) today announced the appointment of Dr. Antony (Tony) Davies as Senior Vice President, UK CMC, effective January 10, 2022.
  • The UK Chemistry, Manufacturing and Control (CMC) business includes operations in Hoddesdon and Cramlington, UK.
  • Tony has been Senior Vice President, Process R&D, since 2019, having been promoted from Vice President, Process Chemistry, a post he held since Pharmaron acquired the MSD Hoddesdon site in 2016.
  • The UK CMC business currently includes operations in Hoddesdon and Cramlington, UK.

Regis Expands Facilities to Support Rising Demand for U.S.-Based Custom API Pharmaceutical Development and Manufacturing

Retrieved on: 
Wednesday, February 17, 2021
Research, Infectious diseases, Clinical trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Articles, Natural sciences, Chemistry, Clinical data management, Clinical research, Pharmaceutical industry, Quality, Validation, Validity, Process chemistry, Chemist, API

It increases capabilities across Regis custom pharmaceutical service offerings, including analytical development, process chemistry, solid state chemistry , validation, stability studies, and commercialization.

Key Points: 
  • It increases capabilities across Regis custom pharmaceutical service offerings, including analytical development, process chemistry, solid state chemistry , validation, stability studies, and commercialization.
  • View the full release here: https://www.businesswire.com/news/home/20210217005052/en/
    Siead Zegar, Director of Process Chemistry at Regis Technologies, in the companys 9,000-square-foot expansion of its custom API development laboratories in Morton Grove, IL.
  • (Photo: Business Wire)
    Regis specializes in serving the API development and manufacturing needs of mid-sized and emerging pharmaceutical and biotechnology companies.
  • We offer a full range of services to support the development of our clients' lead molecules from preclinical and clinical API through commercialization, including process research and development, solid state chemistry, analytical development, stability services, GMP API manufacturing, and micronization.